what is an announcement bar


INTEGRATE Research Trial Update

The INTEGRATE Trial is helping answer an important health question. It has provided evidence that a new treatment, regorafenib, acts against advanced oesophago-gastric cancer and is safe. The investigators are now confident that they can look into a larger trial investigating survival. The trial recruited 152 patients from Australia, New Zealand, Korea and Canada. Patients were randomly allocated to regorafenib or a placebo tablet. Two thirds of the participants were put on the trial drug. All had advanced disease that had come back after chemotherapy. Of the patients taking regorafenib, 46% had no growth in their tumour at 8 weeks, compared with 18% taking placebo. The average overall short term survival was better in the regorafenib.